Posted by Michael Wonder on 23 Dec 2023
Patritumab deruxtecan granted priority review in the US for certain patients with previously treated locally advanced or metastatic EGFR mutated non-small-cell lung cancer
22 December 2023 - Submission based on HERTHENA-Lung01 results showing patritumab deruxtecan demonstrated clinically meaningful and durable responses in patients with advanced EGFR mutated non-small-cell lung cancer previously treated with two or more systemic therapies.
Daiichi Sankyo and Merck announced today that the US FDA has accepted and granted priority review to the biologics license application for patritumab deruxtecan for the treatment of adult patients with locally advanced or metastatic EGFR mutated non-small cell lung cancer previously treated with two or more systemic therapies.
